Business Context and Reporting Period
This Form 8-K Current Report was filed by Inmed Pharmaceuticals Inc. on August 12, 2021. The company is incorporated in British Columbia and its common shares trade on The Nasdaq Stock Market LLC under the symbol INM. The filing serves as a Regulation FD disclosure regarding an upcoming corporate presentation.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or performance metrics.
Material Changes
No material changes to financial position or operations are reported in this document. The filing solely announces a scheduled presentation by company executives.
Guidance, Outlook, and Management Commentary
- Upcoming Event: Eric A. Adams (President and CEO) and Dr. Eric Hsu (Senior Vice President of Pre-Clinical Research & Development) are scheduled to present at the H.C. Wainwright Ophthalmology Virtual Conference.
- Date: Tuesday, August 17, 2021.
- Legal Status: The information, including the news release (Exhibit 99.1), is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, nor is it incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the date and time of the H.C. Wainwright Ophthalmology Virtual Conference presentation.
- Review the full text of the news release (Exhibit 99.1) for specific details on the company's pre-clinical research updates.
- Confirm the company's status as an emerging growth company (indicated as yes in the filing).